How AI and robotics designed new cancer therapies

The latest episode of the DDW 'In Conversation With' series is available to listen to below. This week, Bruno Quinney speaks to Angus Sinclair, Chief Scientific Officer at LabGenius Therapeutics. LabGenius is a biotech using AI and robotics to design new cancer therapies, and in vivo efficacy data reveals the company's novel T-cell engager shows complete tumour elimination in mice. Bruno talks to Angus about what T-cell engagers actually are, how AI is driving the company's approach, and why non-intuitive protein design is emerging within immuno-oncology drug development.   You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.